Search for: "SHIRE U.S., INC." Results 1 - 20 of 66
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Jan 2023, 6:13 am by Unknown
As for Ryne Miller, he said Miller is employed by Debtor West Realm Shires, Inc., “but has no day-to-day responsibilities. [read post]
1 Jun 2021, 12:14 pm by Rohini Kurup
  Demonstrated commitment to advancing technology policies and practices that protect civil rights, civil liberties and democratic values, with expertise in U.S. privacy law (expertise in civil rights law a plus; expertise in non-U.S. privacy law a plus). [read post]
12 Mar 2020, 6:49 am by Rebecca Tushnet
These cash distributions are contractually required by the U.S. government...So if you don’t collect someone else will. [read post]
17 Jun 2019, 7:36 am by Dan Bressler
” “Cotchett Pitre Lawyers Deride Apple’s Sanctions Request as ‘Manufactured Controversy‘” — “Apple Inc. has sought sanctions against principals Joseph Cotchett and Mark Molumphy for what it claims was their ‘blatant and very serious violation’ of a protective order in lawsuits coordinated before U.S. [read post]
29 Mar 2018, 7:05 am by Leonard Gordon and Mary Gardner
A recent decision in an antitrust case brought by the FTC in the U.S. [read post]
23 Mar 2018, 10:54 am by Altman & Altman
– $465M settlement Shire Pharmaceuticals LLC – $350M settlement Allied Home Mortgage – $268M verdict eClinicalWorks – $155M settlement Life Care Centers of America Inc. [read post]
23 Mar 2018, 10:54 am by Altman & Altman
– $465M settlement Shire Pharmaceuticals LLC – $350M settlement Allied Home Mortgage – $268M verdict eClinicalWorks – $155M settlement Life Care Centers of America Inc. [read post]
1 Dec 2017, 11:35 am by Nate Nead
China’s Sanpower Group Co., Ltd. acquired Dendreon Pharmaceuticals Inc for $0.8 billion, and Sumitomo Dainippon Pharma Co., Ltd. acquired Tolero Pharmaceuticals Inc. for $0.8 billion to assist Sumitomo to refresh its pipeline.[28] In Q4 2017, a few M&A transactions have occurred in the pharma deal market. [read post]
15 Feb 2017, 2:49 pm by Thomas Long
Thomas LongCCHPharmaceuticals company Watson’s proposed generic version of competitor Shire’s brand-name mesalamine LIALDA® did not satisfy the requirements for a Markush group claimed by a Shire patent, the U.S. [read post]